CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
80 hedge funds and large institutions have $314M invested in Cymabay Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
25% more funds holding
Funds holding: 64 → 80 (+16)
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
Holders
80
Holding in Top 10
4
Calls
$393K
Puts
$148K
Top Buyers
| 1 | +$10.1M | |
| 2 | +$5.42M | |
| 3 | +$4.8M | |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$3.95M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$3.27M |
Top Sellers
| 1 | -$15.1M | |
| 2 | -$4.03M | |
| 3 | -$3.64M | |
| 4 |
Renaissance Technologies
New York
|
-$3.46M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.4M |